Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Myriad Genetics (MYGN) Operating Margin (2016 - 2026)

Myriad Genetics has reported Operating Margin over the past 17 years, most recently at 2.72% for Q4 2025.

  • Quarterly Operating Margin rose 1580.0% to 2.72% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 46.96% through Dec 2025, down 3223.0% year-over-year, with the annual reading at 46.96% for FY2025, 3222.0% down from the prior year.
  • Operating Margin was 2.72% for Q4 2025 at Myriad Genetics, up from 11.33% in the prior quarter.
  • Over five years, Operating Margin peaked at 2.72% in Q4 2025 and troughed at 154.48% in Q2 2025.
  • The 5-year median for Operating Margin is 17.89% (2024), against an average of 28.82%.
  • Year-over-year, Operating Margin skyrocketed 6230bps in 2021 and then plummeted -13722bps in 2025.
  • A 5-year view of Operating Margin shows it stood at 26.8% in 2021, then decreased by -10bps to 29.36% in 2022, then skyrocketed by 46bps to 15.97% in 2023, then decreased by -16bps to 18.52% in 2024, then skyrocketed by 85bps to 2.72% in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Operating Margin are 2.72% (Q4 2025), 11.33% (Q3 2025), and 154.48% (Q2 2025).